These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 24631451)

  • 21. HPV-genotypes in high-grade intraepithelial cervical lesions in Danish women.
    Kirschner B; Schledermann D; Holl K; Rosenlund M; Raillard A; Quint W; Molijn A; Jenkins D; Junge J
    Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1032-40. PubMed ID: 23647074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment.
    Kreimer AR; Schiffman M; Herrero R; Hildesheim A; González P; Burk RD; Porras C; Sherman ME; Demuth F; Cheung L; Bratti C; Cecilia Rodríguez A
    Int J Cancer; 2012 Jul; 131(1):211-8. PubMed ID: 21823117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of residual/recurrent disease by HPV genotype after loop excision procedure for high-grade cervical intraepithelial neoplasia with negative margins.
    Wu D; Zheng Y; Chen W; Guo C; Yu J; Chen G; Huang Y
    Aust N Z J Obstet Gynaecol; 2011 Apr; 51(2):114-8. PubMed ID: 21466511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
    Tjalma WA; Fiander A; Reich O; Powell N; Nowakowski AM; Kirschner B; Koiss R; O'Leary J; Joura EA; Rosenlund M; Colau B; Schledermann D; Kukk K; Damaskou V; Repanti M; Vladareanu R; Kolomiets L; Savicheva A; Shipitsyna E; Ordi J; Molijn A; Quint W; Raillard A; Rosillon D; De Souza SC; Jenkins D; Holl K;
    Int J Cancer; 2013 Feb; 132(4):854-67. PubMed ID: 22752992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia.
    Fambrini M; Penna C; Pieralli A; Bussani C; Fallani MG; Andersson KL; Scarselli G; Marchionni M
    Gynecol Oncol; 2008 Apr; 109(1):59-64. PubMed ID: 18255129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
    Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
    BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of vaccine human papillomavirus genotypes in squamous intraepithelial lesions (CIN2-3).
    González-Bosquet E; Esteva C; Muñoz-Almagro C; Ferrer P; Pérez M; Lailla JM
    Gynecol Oncol; 2008 Oct; 111(1):9-12. PubMed ID: 18684497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia.
    Huang HJ; Tung HJ; Yang LY; Chao A; Tang YH; Chou HH; Chang WY; Wu RC; Huang CC; Lin CY; Liao MJ; Chen WC; Lin CT; Chen MY; Huang KG; Wang CJ; Chang TC; Lai CH
    Int J Cancer; 2021 Feb; 148(3):665-672. PubMed ID: 32781482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
    Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy.
    Carozzi FM; Tornesello ML; Burroni E; Loquercio G; Carillo G; Angeloni C; Scalisi A; Macis R; Chini F; Buonaguro FM; Giorgi Rossi P;
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2389-400. PubMed ID: 20826836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-treatment human papillomavirus status and recurrence rates in patients treated with loop electrosurgical excision procedure conization for cervical intraepithelial neoplasia.
    Du R; Meng W; Chen ZF; Zhang Y; Chen SY; Ding Y
    Eur J Gynaecol Oncol; 2013; 34(6):548-51. PubMed ID: 24601049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3.
    Alonso I; Torné A; Puig-Tintoré LM; Esteve R; Quinto L; Campo E; Pahisa J; Ordi J
    Gynecol Oncol; 2006 Nov; 103(2):631-6. PubMed ID: 16780934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China.
    Zhang J; Zhang D; Yang Z; Wang X; Wang D
    BMC Cancer; 2020 May; 20(1):443. PubMed ID: 32429919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
    Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
    J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China.
    Chen M; Li C; Cui Q; Zhou C; Chen P; Yao S
    Eur J Obstet Gynecol Reprod Biol; 2023 Jul; 286():10-15. PubMed ID: 37159990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human papillomavirus genotyping as a reliable prognostic marker of recurrence after loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia (CIN2-3) especially in postmenopausal women.
    Kang WD; Kim SM
    Menopause; 2016 Jan; 23(1):81-6. PubMed ID: 26057824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
    Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
    BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.